AN2 Therapeutics, Inc.
ANTXNASDAQHealthcare● Active
$4.90
+$0.16(+3.38%)
Market Cap$134269918
P/E Ratio—
52W High$6.91
52W Low$1
AN2 Therapeutics, Inc. (ANTX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ANTX · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.04B) | ($0.05B) | ($0.06B) | ($0.04B) | ($0.02B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | ($0.00B) | $0.01B | $0.00B | $0.00B |
| Net Cash from Operations | ($0.03B) | ($0.05B) | ($0.05B) | ($0.03B) | ($0.02B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Purchases of Investments | ($0.05B) | ($0.05B) | ($0.13B) | ($0.09B) | ($0.08B) |
| Sales of Investments | $0.07B | $0.10B | $0.09B | $0.07B | $0.03B |
| Net Cash from Investing | $0.03B | $0.05B | ($0.04B) | ($0.02B) | ($0.05B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.00B | $0.00B | $0.08B | $0.07B | $0.08B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.03B) | ($0.05B) | ($0.05B) | ($0.03B) | ($0.02B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · B
Explore more AN2 Therapeutics, Inc. data
About AN2 Therapeutics, Inc. (ANTX) Cash Flow Statement
AN2 Therapeutics, Inc. generated operating cash flow of ($0.03B) and free cash flow of ($0.03B) for 2025 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
ANTX · 4 questionsAN2 Therapeutics, Inc. generated free cash flow of ($0.03B) for 2025, up 39.4% year-over-year.
ANTX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15